Literature DB >> 20959954

[Early detection of prostate cancer: is serum PSA testing alone sufficient?].

C Börgermann1, F Vom Dorp, G Breuer, S Kliner, H Rübben.   

Abstract

The euphoria over PSA as an optimal marker for prostate cancer is gone. Measuring PSA levels has several deficiencies in detecting prostate cancer. First results of the randomized studies ERSPC and PLCO were not able to conclusively prove the value of PSA-based screening. Many attempts have been made to optimize early detection of prostate cancer like using modern imaging techniques or new biomarkers. This review deals with PSA isoforms und emerging biomarkers for the diagnosis of prostate cancer. Despite the inadequacies of PSA it is still the most important marker for the early detection of prostate cancer. Modern biomarkers with the ability to reliably predict aggressive prostate cancer are still missing.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20959954     DOI： 10.1007/s00120-010-2394-5

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  31 in total

1.  Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma.

Authors:  Kishor Mistry; Greg Cable
Journal:  J Am Board Fam Pract       Date:  2003 Mar-Apr

2.  The f/t-PSA ratio in diagnosis of in-patients and out-patients: a unitary cutoff value is not useful!

Authors:  C Börgermann; A Swoboda; H-J Luboldt; F vom Dorp; H Rübben
Journal:  World J Urol       Date:  2009-06-28       Impact factor: 4.226

3.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

Authors:  W J Catalona; A W Partin; K M Slawin; M K Brawer; R C Flanigan; A Patel; J P Richie; J B deKernion; P C Walsh; P T Scardino; P H Lange; E N Subong; R E Parson; G H Gasior; K G Loveland; P C Southwick
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

4.  The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.

Authors:  C Stephan; M Lein; K Jung; D Schnorr; S A Loening
Journal:  Cancer       Date:  1997-01-01       Impact factor: 6.860

5.  Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.

Authors:  René Raaijmakers; Mark F Wildhagen; Kazuto Ito; Alvaro Pàez; Stijn H de Vries; Monique J Roobol; Fritz H Schröder
Journal:  Urology       Date:  2004-02       Impact factor: 2.649

6.  The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance.

Authors:  Martijn P M Q van Gils; Daphne Hessels; Onno van Hooij; Sander A Jannink; W Pim Peelen; Suzanne L J Hanssen; J Alfred Witjes; Erik B Cornel; Herbert F M Karthaus; Geert A H J Smits; Gerhard A Dijkman; Peter F A Mulders; Jack A Schalken
Journal:  Clin Cancer Res       Date:  2007-02-01       Impact factor: 12.531

7.  Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

Authors:  William J Catalona; Jerome P Richie; Frederick R Ahmann; M'Liss A Hudson; Peter T Scardino; Robert C Flanigan; Jean B DeKernion; Timothy L Ratliff; Louis R Kavoussi; Bruce L Dalkin; W Bedford Waters; Michael T MacFarlane; Paula C Southwick
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

8.  Aggressiveness of inflammation in histological prostatitis--correlation with total and free prostate specific antigen levels in men with biochemical criteria for prostate biopsy.

Authors:  G Stimac; A Reljic; B Spajic; J Dimanovski; B Ruzic; M Ulamec; Z Sonicki; O Kraus
Journal:  Scott Med J       Date:  2009-08       Impact factor: 0.729

9.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

10.  Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial.

Authors:  L Määttänen; M Hakama; T L J Tammela; M Ruutu; M Ala-Opas; H Juusela; P Martikainen; U-H Stenman; A Auvinen
Journal:  Br J Cancer       Date:  2007-01-15       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.